Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Soumaya Jadoui; Ophélie Le Chapelain; Véronique Ollivier; Ali Mostefa-Kara; Lucas Di Meglio; Sébastien Dupont; Angèle Gros; Mialitiana Solo Nomenjanahary; Jean-Philippe Desilles; Mikaël Mazighi; Bernhard Nieswandt; Stéphane Loyau; Martine Jandrot-Perrus; Pierre H Mangin; Benoit Ho-Tin-Noé

doi:10.3324/haematol.2020.270439

Glenzocimab does not impact glycoprotein VI-dependent inflammatory haemostasis

Haematologica. 2021 Jul 1;106(7):2000-2003. doi: 10.3324/haematol.2020.270439.

Authors

Soumaya Jadoui¹, Ophélie Le Chapelain¹, Véronique Ollivier¹, Ali Mostefa-Kara¹, Lucas Di Meglio¹, Sébastien Dupont¹, Angèle Gros¹, Mialitiana Solo Nomenjanahary¹, Jean-Philippe Desilles², Mikaël Mazighi², Bernhard Nieswandt³, Stéphane Loyau¹, Martine Jandrot-Perrus¹, Pierre H Mangin⁴, Benoit Ho-Tin-Noé⁵

Affiliations

¹ Université de Paris, LVTS, Inserm U1148, F-75018 Paris.
² Université de Paris, LVTS, Inserm U1148, F-75018 Paris, France; Rothschild Foundation Hospital, Paris, France. Department of Interventional Neuroradiology.
³ University Hospital Würzburg, Rudolf Virchow Center for Experimental Biomedicine, Würzburg.
⁴ Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, F-67065 Strasbourg, France.
⁵ Université de Paris, LVTS, Inserm U1148, F-75018 Paris. benoit.ho-tin-noe@inserm.fr.

Abstract

Not available.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized*
Blood Platelets*
Glycoproteins
Hemostasis*
Humans
Inflammation*

Substances

Antibodies, Monoclonal, Humanized
Glycoproteins
glenzocimab

Grants and funding

Funding: this work was supported by grants from INCA (2016-09/435/NI-KA), La Fondation ARC (PJA 20151203107), La Fondation pour la Recherche Médicale (grant #DPC20171138959), and by public grants overseen by the French National Research Agency (ANR) as part of the Investments for the Future program (PIA) under grant agreement No. ANR-18-RHUS-0001 (RHU Booster) and BPI (CMI2 project TherAVC2.0); SJ was awarded a grant from la Société Française d’Hématologie.